東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Characterization of N-acetyltransfer...

University of Louisville.

Linked to FindBook

Google Book

Amazon

博客來

Characterization of N-acetyltransferase 1 (NAT1) expression in breast cancer.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Characterization of N-acetyltransferase 1 (NAT1) expression in breast cancer./
Author:	Zhang, Xiaoyan.
Description:	124 p.
Notes:	Source: Dissertation Abstracts International, Volume: 69-03, Section: B, page: 1591.
Contained By:	Dissertation Abstracts International69-03B.
Subject:	Health Sciences, Oncology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoeng/servlet/advanced?query=3308342
ISBN:	9780549548270

Characterization of N-acetyltransferase 1 (NAT1) expression in breast cancer.
Zhang, Xiaoyan.

Characterization of N-acetyltransferase 1 (NAT1) expression in breast cancer. - 124 p.

Source: Dissertation Abstracts International, Volume: 69-03, Section: B, page: 1591.

Thesis (Ph.D.)--University of Louisville, 2008.

In summary, high levels of GATA3, XBP1, TFF3, FOXA1, NAT1 and ESR1 expression in ER(+) breast tumors is likely due to the genesis of these tumors from luminal epithelium in the differentiated mammary gland duct.

ISBN: 9780549548270Subjects--Topical Terms:

1018566
Health Sciences, Oncology.

Characterization of N-acetyltransferase 1 (NAT1) expression in breast cancer.
LDR:03136nam 2200277 a 45 001 858198
005 20100712
008 100712s2008 ||||||||||||||||| ||eng d
020 $a 9780549548270
035 $a (UMI)AAI3308342
035 $a AAI3308342
040 $a UMI $c UMI
100 1 $a Zhang, Xiaoyan. $3 1025232
245 1 0 $a Characterization of N-acetyltransferase 1 (NAT1) expression in breast cancer.
300 $a 124 p.
500 $a Source: Dissertation Abstracts International, Volume: 69-03, Section: B, page: 1591.
502 $a Thesis (Ph.D.)--University of Louisville, 2008.
520 $a In summary, high levels of GATA3, XBP1, TFF3, FOXA1, NAT1 and ESR1 expression in ER(+) breast tumors is likely due to the genesis of these tumors from luminal epithelium in the differentiated mammary gland duct.
520 $a Microarray analyses of gene expression profiles have grouped breast cancers into distinct subtypes. The luminal subtype breast cancer is characterized by high expression of N-acetyltransferase 1 (NAT1) and estrogen receptor 1 (ESR1). NAT1 codes for a Phase II drug metabolizing enzyme that N-acetylates and O-acetylates environmental carcinogens and pharmaceutical drugs. ESR1 encodes estrogen receptor (ER), a well established endocrine therapy response predictor associated with better prognosis among breast cancer patients. Besides ER, NAT1 might potentially be an independent prognosis biomarker for breast cancer.
520 $a In this dissertation, we used freshly obtained human breast tumor and normal tissue pairs to characterize NAT1 expression. NAT1 was confirmed to be highly expressed in 75% of ER(+) breast cancer. ER(-) breast cancer did not have high NAT1 expression. Despite the correlation between ESR1 and NAT1 expression, NAT1 did not appear to serve as an estrogen responsive gene. Along with high expression of both ESR1 and NAT1 in luminal subtype breast cancer, numerous transcription factors (GATA3, XBP1, TFF3, FOXA1 (HNF3A)) were also highly expressed. The similarity of these gene expression patterns in breast cancer may suggest they are part of the cell phenotype and some common transcription factors might regulate luminal/ESR1(+) cluster gene expressions that contribute to ER(+) breast cancer phenotype (Chapter I). Several mechanisms were ruled out to possibly induce NAT1 expression in breast cancer although NATb is the major promoter responsible for high NAT1 expression in breast cancer (Chapter II). We did not observe any differences of mRNA stability when comparing malignant and non-malignant breast cell lines. In addition, NAT1 mRNA stability was not influenced by breast cell lines harboring two SNPs in the 3'-UTR region at position 1088 and 1095 (NAT1*10). Further characterization by using allele specific expression in HepG2 cells which is NAT1*4/*10 heterozygote did not show any mRNA stability difference between NAT1*10 and NAT1*4 allele (Chapter III).
590 $a School code: 0110.
650 4 $a Health Sciences, Oncology. $3 1018566
650 4 $a Health Sciences, Pharmacology. $3 1017717
690 $a 0419
690 $a 0992
710 2 $a University of Louisville. $3 1017614
773 0 $t Dissertation Abstracts International $g 69-03B.
790 $a 0110
791 $a Ph.D.
792 $a 2008
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoeng/servlet/advanced?query=3308342